GCOM is one of the most relevant international congresses dedicated to Idiopathic Inflammatory Myopathies (IIM), bringing together around 700 attendees from approximately 50 countries. The audience included clinicians, researchers, young investigators, students, laboratory professionals, industry representatives, patient organizations, and foundations.
Werfen was present with a dedicated booth and was the only IVD company exhibiting at GCOM 2026. Although our presence was focused and targeted, the booth represented an important opportunity to engage directly with leading myositis experts, current collaborators, customers, and key stakeholders in the field.
The congress covered several topics highly relevant to autoimmune diagnostics, including:
Clinical care and research in idiopathic inflammatory myopathies
Myositis classification and epidemiology
Muscle imaging and clinical trials
Organ involvement and patient perspectives
Current and emerging therapies
The role of autoantibodies in myositis diagnosis and patient stratification
The need for reliable and clinically meaningful diagnostic solutions
Werfen’s participation at GCOM reinforced our commitment to the myositis community and supported our ongoing efforts to stay aligned with the latest scientific advances in autoimmune diagnostics. The congress also provided a valuable opportunity for KOL mapping and engagement in a highly specialized area where comprehensive autoantibody profiling continues to play an increasingly important role.